Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-27T19:41:13.771Z Has data issue: false hasContentIssue false
  • English
  • Français

Finnish Breast Cancer Group (FBCG)

Published online by Cambridge University Press:  04 December 2006

Abstract

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Finnish Breast Cancer Group (FBCG). Clinical trials include:

  1. Comparison of vinorelbine versus docetaxel, and trastuzumab versus no trastuzumab as adjuvant treatments of early breast cancer. FinHer study

  2. Randomized phase III study comparing single-agent docetaxel followed by 5-FU, epirubicin and cyclophosphamide (FEC) to docetaxel plus Xeloda followed by cyclophosphamide, epirubicin and Xeloda (CEX) as adjuvant treatment for early breast cancer. FinXX Study

  3. A multicenter phase III open randomised trial of the efficacy of exercise in the prevention of long-term adverse effects of adjuvant treatments and breast cancer recurrences in women with primary breast cancer. BREX 01-2004 Study

Type
Other
Information
Breast Cancer Online , Volume 9 , Supplement S1: AN OVERVIEW OF RECENT AND ONGOING CLINICAL TRIALS FOR BREAST CANCER 4th EDITION , December 2006 , pp. 131 - 137 , e55
Copyright
© 2006 Cambridge University Press

FBCG – Contact Details

Country

Finland

Chair

Dr R. Huovinen, Turku University Hospital, Department of Oncology, P.O. Box 52, FIN-20521 TURKU, FINLAND. Tel: +358 2 313 0000 Fax: +358 2 313 2809 Email:

Other Subgroup Head/Member: (Please Specify)

Vice Chair, Trial Coordinator:

Professor H. Joensuu, Helsinki University Central Hospital, Department of Oncology, Haartmaninkatu 4, P.O. Box 180, FIN-00029 HELSINKI, FINLAND. Tel: +358 9 4717 3200 Email:

FBCG Treasurer, BIG Voting Representative:

Adjunct Professor M. Tanner, Tampere University Hospital, Department of Oncology, P.O. Box 2000, FIN-33521 TAMPERE, FINLAND. Tel: +358 3 3116 7640 Fax: +358 3215 8923 Email:

Trial Coordinator:

Adjunct Professor T. Saarto, Helsinki University Central Hospital, Department of Oncology, Haartmaninkatu 4, P.O. Box 180, FIN-00029 HELSINKI, FINLAND. Tel: +358 39 4711 Email:

Secretary:

Dr P. Auvinen, Kuopio University Hospital, Department of Oncology, P.O. Box 1777, FIN – 70211, KUOPIO, FINLAND. Tel: +358 17 173 311 Email:

FBCG – Study Details

Title

Comparison of vinorelbine versus docetaxel, and trastuzumab versus no trastuzumab as adjuvant treatments of early breast cancer.

FinHer study

Coordinator(s)

H. Joensuu, Helsinki University Central Hospital, Department of Oncology, Haartmaninkatu 4, P.O. Box 180, FIN-00029 HELSINKI, FINLAND. Tel: +358 9 4717 3200

Summary

  • Opened in November 2000
  • Target accrual: 1010 patients

Objectives

  • To compare tolerability, safety and efficacy of single-agent vinorelbine and single-agent docetaxel as adjuvant treatments of early breast cancer with moderate to high risk for cancer recurrence.
  • To assess tolerability, safety and efficacy of trastuzumab given concomitantly with vinorelbine or docetaxel as adjuvant treatment of early breast cancer with moderate to high risk for cancer recurrence.

Scheme

Update

  • Study closed in September 2003 with 1010 patients (1009 eligible).
  • Three-year results have been published (Joensuu H et al., New Engl J Med 2006; 354: 809–820).

Related Publications

Joensuu H et al., New Engl J Med 2006; 354: 809–820.

Topics

  • HER2 positive patients
  • Taxanes
  • Trastuzumab
  • Vinorelbine
  • Cardiac function
  • Anthracyclines
  • Innovative schedules

Keywords

Adjuvant treatment, HER-2 positive breast cancer, trastuzumab

***************************************************

Title

Randomized phase III study comparing single-agent docetaxel followed by 5-FU, epirubicin and cyclophosphamide (FEC) to docetaxel plus Xeloda followed by cyclophosphamide, epirubicin and Xeloda (CEX) as adjuvant treatment for early breast cancer.

FinXX Study

Coordinator(s)

H. Joensuu, Helsinki University Central Hospital, Department of Oncology, Haartmaninkatu 4, P.O. Box 180, FIN-00029 HELSINKI, FINLAND. Tel: +358 9 4717 3200

Summary

  • Opened in January 2004
  • Target accrual: 1500 patients

Objectives

  • Primary endpoint: relapse-free survival (RFS) at 5 years.
  • Secondary endpoint: safety and overall survival.

Scheme

Update

  • Study ongoing, 977 patients accrued by the end of February 2006.

Related Publications

None available

Topics

  • Capecitabine
  • Taxanes

Keywords

Adjuvant treatment, capecitabine, taxanes

***************************************************

Title

A multicenter phase III open randomised trial of the efficacy of exercise in the prevention of long-term adverse effects of adjuvant treatments and breast cancer recurrences in women with primary breast cancer.

BREX 01-2004 Study

Coordinator(s)

T. Saarto, C. Blomqvist, Helsinki University Central Hospital, Department of Oncology, Haartmaninkatu 4, P.O. Box 180, FIN-00029 HELSINKI, FINLAND. Tel: +358 9 4711

Summary

  • Opened in December 2005.
  • Target accrual: 600 patients (300 per arm).
  • Patients are randomised into exercise intervention or control groups. The exercise intervention consists of both supervised and home training. The control group maintain previous physical activity and exercise habits.

Objectives

  • To investigate whether regular exercise after adjuvant treatments of breast cancer could:

        (1) prevent osteoporosis (primary outcome)

        (2) improve quality of life (primary outcome)

        (3) improve weight control, and muscular and cardiovascular fitness (secondary outcome)

        (4) reduce the risk of breast cancer recurrence (secondary outcome)

        (5) prevent other diseases and reduce all-cause mortality in patients with primary breast cancer (secondary outcome)

Scheme

None available

Update

  • Study ongoing

Related Publications

None available

Topics

  • Bone mineral density

Keywords

Intervention, prevention, primary breast cancer, osteoporosis